Wall Street brokerages expect that Alimera Sciences Inc (NASDAQ:ALIM) will announce sales of $5.14 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Alimera Sciences’ earnings, with estimates ranging from $2.25 million to $8.02 million. Alimera Sciences reported sales of $10.86 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 52.7%. The business is expected to announce its next earnings results on Monday, August 3rd.
On average, analysts expect that Alimera Sciences will report full-year sales of $50.07 million for the current financial year, with estimates ranging from $48.29 million to $51.84 million. For the next financial year, analysts forecast that the company will report sales of $63.16 million, with estimates ranging from $60.05 million to $66.26 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Alimera Sciences.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.19. The business had revenue of $14.54 million during the quarter, compared to analysts’ expectations of $14.04 million.
NASDAQ:ALIM traded down $0.10 during trading hours on Friday, hitting $6.39. The stock had a trading volume of 57,791 shares, compared to its average volume of 42,449. Alimera Sciences has a 1-year low of $2.86 and a 1-year high of $14.82. The business has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $5.91. The company has a market cap of $32.15 million, a PE ratio of -3.53 and a beta of 2.20.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Read More: Convertible Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.